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Abstract
Background: We aimed to evaluate the effects of the G-allele of rs6232 and the C-allele of rs6235 within PCSK1 on measures
of body fat and glucose homeostasis in Danish individuals and to assess interactions of genotypes with age, sex and glucose
tolerance status. Data were included in meta-analyses of additional Europeans.
Methodology/Principal Findings: Rs6232 and rs6235 were genotyped in 6,164 Danes from the Inter99 study of middle-
aged people. Results from these analyses were combined with previously published studies in meta-analyses of a total of
27,786 individuals. The impact of the variants was also investigated in a subset of 62 glucose-tolerant men during a meal
challenge including measures of serum incretins. In men we found an effect on body composition in sex-stratified analyses
where the rs6235 C-allele conferred an increased waist circumference of 0.8 cm per allele (0.2–1.5, p=0.008) and increased
waist-to-hip ratio of 0.004 (0.0005–0.008, p=0.027). In the meta-analyses where men and women were combined, the
rs6232 G-allele associated with increased waist-to-hip ratio (p=0.02) and the rs6235 C-allele associated with increased waist
circumference (p=0.01). Furthermore, the rs6235 C-allele was associated nominally with a 0.6% (0.1–1%, p=0.01) reduction
in fasting glucose, it interacted with glucose tolerance status for traits related to glucose metabolism and analysis among
individuals having abnormal glucose tolerance revealed a 5% (20.7–9%, p=0.02) elevated level of acute insulin response for
this variant. Finally, we found that the rs6232 G-allele associated with higher levels of GLP-1, GLP-2 and glucagon and that
the rs6235 C-allele associated with higher levels of GIP and glucagon during a meal-test.
Conclusions/Significance: PCSK1 rs6232 G-allele and rs6235 C-allele have an effect on body composition which may be
modified by sex, whereas the effect of rs6235 C-allele on fasting and stimulated circulating plasma glucose and hormone
levels may be influenced by glucose tolerance status.
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Introduction
PCSK1 encodes the proprotein convertase 1/3 (PC1/3) which is
involved in the tissue-specific processing of several prohormones
and neuropeptide precursors [1,2]. PC1/3 is a subtilisin-like
endoprotease responsible for processing large precursor proteins
into bioactive products. The processing of proinsulin and pro-
opiomelanocortin (POMC) as well as the precursors of glucagon-
like-peptide 1 (GLP-1) and glucose-dependent insulinotropic
polypeptide (GIP) are known key functions of PC1/3 [2,3].
Rare mutations in PCSK1 are leading to PC1/3 deficiency.
This results in obesity as well as other abnormalities such as
dysregulated glucose homeostasis and small intestinal dysfunction
confirming the importance of PC1/3 for the maturation of
hormones regulating body weight and glucose homeostasis [4–6].
PCSK1 was suspected as an obesity risk gene in linkage studies
identifying an obesity-region located on chromosome 5 including
the PCSK1-locus [7,8]. Subsequently, in a meta-analysis combining
eight independent studies and comprising a total of 13,659 Euro-
peans two common non-synonymous variants, rs6232, encoding
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e23907N221D, and rs6235, encoding the Q665E-S690T pair, within
PCSK1 were reported to associate with an increased risk of obesity
with an OR of 1.34 and 1.22, respectively (the G-allele of rs6232:
p=7.27 * 10
28 and the C-allele rs6235: p=2.31 * 10
212) [9].
Functional analysis of the N221D-mutant in transfected HEK293T
cells showed a significant 10.4% impairment of the activity of the
recombinant PC1/3 protein whereas rs6235 in the same in vitro test
system showed no alterations in response compared with wild type
[9].
The association of these common variants with obesity has been
further investigated, however, with ambiguous results. A Swedish
study among 4,923 individuals found no association between the
rs6235 C-allele and BMI [10], yet, reported a nominally signifi-
cant protective effect for developing type 2 diabetes [10]. Another
study failed to show strong associations of both variants with
obesity in an analysis comprising 20,249 individuals from the
United Kingdom [11]. Yet, this study observed an association
between rs6232 and obesity among younger individuals and not
among the older, and also that rs6235 C-allele was associated with
a higher risk of obesity in women but not in men [11]. Conversely,
in a previously performed case-control study the rs6232 G-allele
was found to be associated with overweight but not obesity, and
Table 1. Association between measures of metabolic traits and the rs6232 G-allele and the rs6235 C-allele of PCSK1 among 6,039
treatment-naı ¨ve Danes.
Rs6232 AA AG GG Effect pr. allele (95% CI) PADD1 PADD2
N (M/W) 5046
(2494/2552)
728
(378/350)
21
(10/11)
Age (years) 46684 6 684 8 67
Body composition
BMI (kg/m
2) 26.264.5 26.464.5 26.763.3 0.2 (20.1;0.5) 0.2 -
Waist (cm) 86613 87613 89611 0.5 (20.4;1) 0.3 -
Waist/hip 0.8560.09 0.8660.09 0.8860.08 0.002 (20.002;0.007) 0.4 -
Measures of glucose homeostasis
*Fasting serum insulin (pmol/l) 34 (24;51) 33 (23;53) 45 (32;57) 1.5 (23;6) 0.5 1.0
*Serum insulin 30 min (pmol/l) 244 (175;353) 246 (178;356) 260 (175;332) 1.1 (23;5) 0.6 0.9
*Serum insulin 120 min (pmol/l) 157 (95;257) 154 (101;239) 174 (106;256) 21.3 (27;5) 0.7 0.4
*Fasting plasma glucose (mmol/l) 5.4 (5.1;5.8) 5.4 (5.1;5.8) 5.8 (5.4;6.0) 20.8 (22;0.01) 0.05 0.02
*Plasma glucose 30 min (mmol/l) 8.6 (7.4;9.8) 8.5 (7.3;9.8) 9.6 (8.5;11.0) 21( 22;0.5) 0.2 0.1
*Plasma glucose 120 min (mmol/l) 5.9 (4.9;7.0) 5.8 (4.9;6.9) 6.3 (5.6;6.9) 0.0 (22;2) 1.0 0.7
*HOMA-IR 8.3 (5.7;12.9) 8.0 (5.5;13.1) 10.2 (7.4;15.0) 20.2 (23;2) 0.8 0.7
*BIGTT-AIR 1618 (1281;2068) 1665 (1322;2164) 1339 (1089;2030) 3 (0;7) 0.05 0.05
*BIGTT-SI 9.2 (6.3;12.1) 9.5 (6.5;11.9) 8.8 (5.5;10.4) 22( 233;29) 0.9 0.9
Rs6235 GG GC CC PADD
N (M/W) 2922
(1426/1496)
2383
(1208/1175)
2383
(1208/1175)
Age (years) 46684 6 684 6 68
Body composition
BMI (kg/m
2) 26.264.5 26.264.5 26.464.8 0.07 (20.1;0.2) 0.5 -
Waist (cm) 86613 87613 87614 0.3 (20.1;0.8) 0.1 -
Waist/hip 0.8560.08 0.8660.09 0.8660.09 0.001 (20.001;0.004) 0.3 -
Measures of glucose homeostasis
*Fasting serum insulin (pmol/l) 34 (24;51) 34 (23;51) 34 (24;49) 0.3 (20.4;3) 0.8 1.0
*Serum insulin 30 min (pmol/l) 240 (174; 351) 249 (176;357) 248 (179;343) 1 (21;3) 0.4 0.5
*Serum insulin 120 min (pmol/l) 156 (96; 259) 157 (95;253) 155 (101;247) 1 (22;5) 0.5 0.6
*Fasting plasma glucose (mmol/l) 5.5 (5.1;5.8) 5.4 (5.1;5.8) 5.5 (5.1;5.8) 20.6 (21;20.1) 0.01 0.004
*Plasma glucose 30 min (mmol/l) 8.5 (7.4;9.8) 8.5 (7.4;9.8) 8.6 (7.5;9.9) 20.00 (21;1) 1.0 0.9
*Plasma glucose 120 min (mmol/l) 5.9 (4.9;6.9) 5.9 (4.9;7.0) 5.8 (4.9;7.0) 0.1 (21;1) 0.9 1.0
*HOMA-IR 8.3 (5.7;12.9) 8.3 (5.5;12.9) 8.2 (5.7;12.4) 20.2 (23;2) 0.9 0.6
*BIGTT-AIR 1602 (1277;2048) 1661 (1300;2137) 1612 (1283;2058) 1 (20.1;3) 0.07 0.07
*BIGTT-SI 9.1 (6.4;12.1) 9.3 (6.3;12.0) 9.3 (6.4;12.0) 24( 22;1) 0.7 0.7
Data are presented as mean 6 SD and as effect sizes (95% CI) for traits following a normal distribution. Remaining traits are presented as median (inter-quartile range)
and their effect sizes are presented as increase/decrease in percentage pr. allele in relation to the value of the major homozygous genotype. Multiple regression analysis
was used to test for difference between genotype groups. PADD1-values are corrected for sex and age. PADD2-values are corrected for sex, age and BMI. *=natural log
transformation.
doi:10.1371/journal.pone.0023907.t001
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weight among 6,514 middle-aged Danes [12]. However, these
associations were not confirmed in a German study among 1,498
individuals [13].
Elevated levels of proinsulin and proinsulin/insulin ratio, lower
circulating glucose level 120 min after glucose ingestion, lower
fasting insulin levels, and reduced insulin sensitivity have also been
reported to be associated with these PCSK1 variants [13].
In light of these equivocal reports, the aim of this study was to
evaluate the effects of the G-allele of rs6232 and the C-allele
of rs6235 within PCSK1 on measures of body fat and glucose
homeostasis in 6,039 middle-aged, treatment-naı ¨ve Danes and in
meta-analyses including 1,498 non-diabetic German individuals
[13] as well as 20,249 population-based study participants from the
UK [11]. As suggested from previous studies, there may be an
interaction of these variants with either age or sex which we also
aimed to evaluate. Moreover, we estimated if the effects of PCSK1
variants differed in glucose tolerant individuals and individuals with
impaired glucose regulation.Inordertofurther elucidate theimpact
of these variants, circulating levels of plasma glucose, serum
proinsulin, serum insulin, plasma GIP, plasma GLP-1 and plasma
glucagon-like-peptide 2 (GLP-2) as well as plasma glucagon were
examined in 62 glucose tolerant men during a meal test.
Methods
Danish study participants
Genotyping of PCSK1 rs6232 and rs6235 was performed in
individuals from the Inter99 study which originally was designed
as a lifestyle intervention trial for cardiovascular disease, registered
at ClinicalTrials.gov, Identifier NCT00289237 [14]. The Inter99
cohort consists of 61,301 subjects aged 30–60 years from the
Danish Civil Registration System in southwestern Copenhagen
County. A sample of 13,016 individuals was randomly selected, of
these 12,934 were invited for an examination as the remaining 82
individuals had died or could not be traced. 6,784 (52.5%)
attended the baseline investigation prior to the start of interven-
tion. Outcome from an oral glucose tolerance test (OGTT), values
Figure 1. Meta-analyses combining the previously observed effect of PCSK1 rs6232 (A) and rs6235 (B) on quantitative
anthropometric traits [11,13].
doi:10.1371/journal.pone.0023907.g001
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available from the baseline examination of the Inter99 study.
Glucose tolerance status was defined according to WHO 1999
criteria [15] (Table S1). For the present study DNA was available
from 6,164 individuals of the Inter99 participants including 4,568
individuals with normal glucose tolerance (NGT), 508 individuals
with impaired fasting glucose (IFG), 707 individuals with impaired
glucose tolerance (IGT), 256 individuals with screen detected
diabetes mellitus (SDM), and 125 with known diabetes mellitus
(KDM). Analyses were performed in treatment-naı ¨ve participants
comprising a total of 6,039 individuals with NGT, IFG, IGT and
SDM.
Study samples included in the quantitative trait
meta-analyses
The study population examined by Heni and colleagues
included a total of 1,498 non-diabetic German individuals [13]
and Kilpela ¨inen and colleagues examined 9,998 men and 10,251
women recruited in Norfold, UK [11].
Meal challenge
The study of circulating levels of glucose and hormones
following a meal test was carried out in 62 glucose tolerant men
recruited from the Inter99 study based on TCF7L2 genotype and
phenotypic characteristics. This subset included 31 men homozy-
Table 2. Interaction analyses for rs6232 and rs6235 of PCSK1 with sex, age and glucose tolerance status for metabolic traits.
rs6232 rs6235
PINT_GENDER PINT_AGE PINT_GLUTOL PINT_GENDER PINT_AGE PINT_GLUTOL
Body composition
BMI (kg/m
2) 0.2 0.3 0.3 0.4
Waist (cm) 0.2 0.5 0.04 0.3
Waist/hip 0.2 0.8 0.02 0.09
Measures of glucose homeostasis
*Fasting serum insulin (pmol/l) 0.2 0.04
*Serum insulin 30 min (pmol/l) 0.6 0.5
*Serum insulin 120 min (pmol/l) 0.5 0.04
*Fasting plasma glucose (mmol/l) 0.9 0.01
*Plasma glucose 30 min (mmol/l) 0.3 0.1
*Plasma glucose 120 min (mmol/l) 0.3 0.02
*HOMA-IR 0.2 0.1
*BIGTT-AIR 0.9 0.04
*BIGTT-SI 0.9 0.3
doi:10.1371/journal.pone.0023907.t002
Table 3. Association between measures of obesity stratified according to sex for the PCSK1 rs6235 among 5,788 treatment-naı ¨ve
Danes.
Rs6235 GG GC CC Effect pr. allele (95% CI) PADD
Men
N 1426 1208 239
Age (years) 46684 7 684 7 68
Body composition
BMI (kg/m
2)2 6 . 6 63.9 26.864.1 27.064.2 0.2 (20.06;0.4) 0.2
Waist (cm) 93611 93611 95611 0.8 (0.2;1.5) 0.008
Waist/hip 0.9160.06 0.9260.07 0.9260.07 0.004 (0.0005;0.008) 0.027
Women
N 1496 1175 244
Age (years) 46684 6 684 6 68
Body composition
BMI (kg/m
2)2 5 . 7 64.9 25.664.9 25.865.2 20.03 (20.3;0.2) 0.8
Waist (cm) 80612 80612 80613 20.2 (20.8;0.5) 0.7
Waist/hip 0.860.06 0.7960.06 0.860.06 20.002 (20.005;0.002) 0.4
Data are presented as mean 6 SD and as effect sizes (95% CI). PADD-values are adjusted for sex and age.
doi:10.1371/journal.pone.0023907.t003
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matched men homozygous for the rs7903146 C-allele [16]. The
62 men were, following an overnight fast, in the morning subjected
to a test meal consisting of 50 g white bread, 50 g black bread,
10 g butter, 40 g cheese, 20 g sugar free jam and 200 ml of milk
(34% fat, 47% carbohydrate, 19% protein), comprising a total of
566 kcal (2370 kJ). The meal was consumed within 15 min.
Arterialized venous blood was drawn 20, 10 and 0 min before and
15, 30, 45, 60, 75, 90, 120, 150, 180, 210 and 240 min after
ingestion of the meal.
Informed written consent was obtained from all subjects before
participation. The study was approved by the Ethical Committee
of Copenhagen County and was in accordance with the principles
of the Helsinki Declaration.
Anthropometrics and biochemical assays
Height and weight were measured in light indoor clothes and
without shoes, and BMI was calculated as weight (kg)/height (m)
2.
Waist circumference at the umbilical level was measured on
participants in an upright position to the nearest 0.5 cm using a
non-extendable linen tape measure according to WHO recom-
mendation.
Blood samples were collected during an OGTT for biochemical
analyses of plasma glucose and serum insulin and during a meal
challenge for analyses of plasma glucose, serum insulin, serum
proinsulin, plasma GIP, plasma GLP-1, plasma GLP-2 and
plasma glucagon. Blood samples were biochemically evaluated as
previously described [16].
Genotyping
The PCSK1 variants were genotyped using KASParH allelic
discrimination (KBioscience, Hoddesdon, UK). The PCSK1 rs6232
and rs6235 had a genotype success rate of 97.1% and 96.7%,
respectively, and an error rate of 0.0% estimated from approxi-
mately 400 duplicate samples for each variant. Both genotypes
obeyed Hardy-Weinberg equilibrium (rs6232: p=0.7; rs6235:
p=0.9). R
2 for the two variants was 0.17.
Calculations
Homeostatic model assessment of insulin resistance (HOMA-
IR) index was calculated as: (Fasting plasma glucose * Fasting
serum insulin)/22.5. The OGTT-derived indices of insulin sensitivity
and beta-cell function, BIGTT-SI and BIGTT-AIR, were calcu-
lated as previously described [17]. The areas under the curves
Table 4. PCSK1 rs6235 stratified measures of metabolic traits among 4,393 glucose tolerant individuals (NGT) and 1,395 Danes
with impaired glucose regulation.
GG GC CC
Effect pr. allele
(95% CI) PADD1 PADD2 PADD3
NGT
N (M/W) 2,210 (995/1,215) 1,815 (866/949) 368 (172/196)
Age (years) 45684 5 684 5 68
Measures of glucose homeostasis
*Fasting serum insulin (pmol/l) 31 (23;46) 31 (22;46) 31 (22;43) 20.9 (23.5;1.7) 0.5 0.09 0.3
*Serum insulin 30 min (pmol/l) 239 (175;345) 248 (179;347) 239 (175;338) 0.6 (21.9; 3.1) 0.6 0.5 0.9
*Serum insulin 120 min (pmol/l) 139 (87;212) 135 (86;210) 142 (93;206) 20.1 (23.4;3.2) 1.0 0.05 0.7
*Fasting plasma glucose (mmol/l) 5.3 (5.1;5.6) 5.3 (5.0;5.6) 5.4 (5.1;5.6) 20.2 (20.6;0.1) 0.2 0.1 0.1
*Plasma glucose 30 min (mmol/l) 8.1 (7.1;9.1) 8.1 (7.1;9.1) 8.2 (7.3;9.3) 20.4 (20.4;1.3) 0.3 0.4 0.4
*Plasma glucose 120 min (mmol/l) 5.6 (4.7;6.4) 5.5 (4.7;6.3) 5.6 (4.8;6.3) 20.4 (21.4;0.6) 0.4 0.4 0.4
*HOMA-IR 7.5 (5.2;11.1) 7.5 (5.1;11.0) 7.5 (5.2;10.3) 21.1 (20.4;1.6) 0.4 0.2 0.2
*BIGTT-AIR 1656 (1345;2083) 1715 (1361;2171) 1621 (1320;2058) 0.5 (21.4;2.4) 0.6 1.0 1.0
*BIGTT-SI 10 (8;13) 10 (8;13) 10 (8;13) 22( 220;16) 0.8 0.4 0.4
IGT, IFG, SDM
N (M/W) 711 (431/280) 568 (342/226) 115 (67/48)
Age (years) 49674 9 675 0 68
Measures of glucose homeostasis
*Fasting serum insulin (pmol/l) 45 (31;68) 48 (30;72) 50 (31;78) 4.8 (20.2;9.8) 0.06 0.09 0.3
*Serum insulin 30 min (pmol/l) 248 (172;378) 256 (166;381) 272 (188;357) 2.8 (22.5;8.1) 0.3 0.5 0.8
*Serum insulin 120 min (pmol/l) 271 (154;444) 273 (174;497) 331 (182;519) 7.2 (0.6;14.0) 0.03 0.05 0.09
*Fasting plasma glucose (mmol/l) 6.2 (5.7;6.5) 6.2 (5.7;6.5) 6.1 (5.6;6.4) 21.4 (22.5;20.2) 0.02 0.009 0.004
*Plasma glucose 30 min (mmol/l) 10 (9;12) 10 (9;11) 10 (9;11) 20.9 (22.4;0.5) 0.2 0.2 0.09
*Plasma glucose 120 min (mmol/l) 8.1 (6.4;9.4) 8.3 (7.0;9.8) 8.2 (7.3;9.4) 2.3 (20.3;4.9) 0.08 0.1 0.1
*HOMA-IR 12 (8;19) 13 (8;20) 14 (8;21) 3.5 (21.9;8.9) 0.2 0.3 0.8
*BIGTT-AIR 1406 (1043;1899) 1413 (1092;1929) 1564 (1105;2049) 5.0 (0.7;9.3) 0.02 - 0.09
*BIGTT-SI 5.7 (3.5;8.0) 5.2 (3.0;8.1) 4.9 (3.2;7.5) 222 (250;5) 0.1 - 0.6
Data are presented as mean 6 SD and as effect sizes (CI) for traits following a normal distribution adjusted for age and sex. Remaining traits are presented as median
(inter-quartile range) and their effect sizes are presented as increase/decrease in percentage in relation to the value of the major homozygous genotype. PADD1-values
are corrected for sex and age. PADD2-values are corrected for sex, age and BMI. PADD3-values are corrected for sex, age and waist. *=natural log transformation.
doi:10.1371/journal.pone.0023907.t004
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AUCs were calculated by subtraction of the fasting values.
Statistical analyses
A general linear model (GLM) was used to test for difference
between genotype groups. All p-values were calculated assuming
an additive model adjusted for sex, age and BMI where appropriate
(PADD) where the beta-value was used as a measure of the effect size.
Traits not applying to a normal distribution (all traits except for
measures of body composition) were natural log-transformed prior
to analysis. The effect sizes of natural log-transformed traits are
presented as a change in % per effect allele in relation to the trait
value of the major homozygous genotype. To investigate whether
the effect of the alleles differed between individuals with different
glucosetolerancestatusand differentsex,weincludedaninteraction
term between sex, age or glucose tolerance status and the variants of
interest in the linear model assuming an additive model. The meta-
analyses were performed combining the effect size estimates and SE
derived from a linear regression analysis for untransformed
quantitative traits for all of the included studies. In the meta-
analyses both fixed effect (weight of studies estimated using inverse
variance) and random effect (weight of studies estimated using
DerSimonian-Laird method) [18] were applied. As subjects under-
going the meal-challenge were selected based on their TCF7L2
rs7903146 genotype, all analyses of meal challenge data were also
performed adjusting for TCF7L2 rs7903146. However, as this did
not influence the results, data shown are adjusted only for age.
Bonferroni correction for multiple testing is assuming complete
independence between included SNPs. However, rs6232 and
rs6235 are not completely independent, as there is a minor linkage
disequilibrium between the two SNPs (r
2=0.17). A method for
correction for multiple testing in SNPs in linkage disequilibrium
have been provided by Nyholt [19] which estimates a factor based
on the spectral decomposition of matrices of pairwise linkage
disequilibrium between SNPs. This factor provides an estimate of
the number of independent tests performed according to the level of
linkage disequilibrium. The factor for rs6232 and rs6235 was 1.83.
Thus, in order to reduce the risk of a type 1 error, a p-value of 0.05/
1.83=0.027 was set as the threshold for significance in the present
study. Statistical analyses were performed using RGui version
2.12.1.
Based on the previously described method for calculating
statistical power [20], the statistical power of the study among the
6,039 treatment naı ¨ve Danes was 80% to detect an allele-specific
difference for rs6232 amounting to 11% and for rs6235 to 6.1% of
a standard deviation per effect allele. This corresponds for rs6232
to a statistical power of 80% to detect the following changes per G-
allele: BMI of 0.50 kg/m
2, waist circumference=1.45 cm, fasting
serum insulin=6.4%, fasting plasma glucose=1.3%, BIGTT-
AIR=4.6%, BIGTT-SI=6.8%; and per C-allele for rs6235 :
BMI=0.28 kg/m
2, waist=0.80 cm, fasting serum insulin=3.6%,
fasting plasma glucose=0.7%, BIGTT-AIR=2.6%, BIGTT-
SI=3.8%.
Results
PCSK1 variants and obesity
To investigate the underlying phenotypes of obesity, we
evaluated the effects of the G-allele of PCSK1 rs6232 and the
C-allele of PCSK1 rs6235 in 6,039 treatment-naı ¨ve Danes on
measures of obesity by applying an additive model adjusted for sex
and age. Neither variant was associated with measures of obesity
among Danes (Table 1); however, when we combined our results
with two previous studies [11,13], the rs6232 G-allele was
significantly associated with increased waist/hip ratio (p=0.02)
and the rs6235 C-allele with increased waist circumference
(p=0.01) (Figure 1). Interaction with sex and age was examined
inspired by previously observed age- and sex-dependent effects of
the rs6232 G-allele and the rs6235 C-allele [11]. In the Danish
study sample significant interaction was only seen between C-allele
of PCSK1 rs6235 and sex for traits related to obesity (Table 2).
Thus, analyses for rs6235 were stratified according to sex and we
found an increased waist circumference of 0.8 cm (95% CI: 0.2–
1.5 cm, p=0.008) and waist-to-hip ratio of 0.004 (0.0005–0.008,
p=0.027) per C-allele among men but not among women from
the Inter99 study population (Table 3).
PCSK1 variants and glucose homeostasis
The effect of PCSK1 variants on measures of glucose homeostasis
wasalsoexaminedandtheC-allele ofrs6235 associated with a 0.6%
(0.1–1%, p=0.01) reduction per allele in fasting plasma glucose
(Table 1). This result was independent of adjustment for BMI
(Table 1).
Traits related to glucose metabolism were also examined for
interactions between the variants and glucose tolerance status
because of the close biological relationship between PC1/3 and
circulating serum incretins. Significant interactions were found
only for rs6235 (Table 2). This variant showed a 1.4% (0.2–2.5%,
p=0.02) lower level of fasting plasma glucose and a 5% (0.7–9%,
p=0.02) increased acute insulin response measured as BIGTT-
AIR per allele among 1,394 individuals having an abnormal
glucose regulation (Table 4). These analyses were independent of
adjustment for BMI (Table 4). Yet, the observed increase in serum
insulin was possibly related to an increased demand of insulin
among men due to their increased waist circumference and indeed
the significant effect of the variant on the serum insulin level
disappeared after adjustment for waist (Table 4).
Measurement of levels of serum proinsulin, serum insulin, plasma
glucose, plasma GIP, plasma GLP-1, plasma GLP-2 and plasma
glucagon following a standardised meal-test were available for a
subgroup of 62 men. The responses of these volunteers were used
for further evaluation of the effect of both the rs6232 and rs6235.
The G-allele of rs6232 was associated withhighermeasures ofGLP-
1 and GLP-2 throughout the time course of the meal-test when
assuming an additive model and when adjusting for age and BMI.
This was reflected in an elevated AUC for GLP-1 as well as an
elevated postprandial AUC (measured as IAUC) for both GLP-1
and GLP-2 among G-allele carriers of the rs6232 (Figure 2). Also,
IAUC for glucagon was significantly elevated among carriers of this
variant (Figure 2). Carriers of the rs6235 C-allele had elevated levels
of IAUC for GIP as well as elevated levels of AUC for glucagon
(Figure 3). We did not find any effect of either variant on proinsulin
(Figure S1) or insulin (Figure 2 and 3).
Discussion
The present study evaluated the effects of the non-synonymous
rs6232 G-allele and the rs6235 C-allele within PCSK1 on measures
Figure 2. Measures of plasma glucose (A), serum insulin (B), plasma GLP-1 (C), and plasma GIP (D), plasma GLP-2 (E) and plasma
glucagon (F) in 62 carriers of PCSK1 rs6232 undergoing a standardized meal test. Data are means 6 standard error. Values for Area Under
the Curve (AUC) and incremental AUC (IAUC) plasma glucose are measured as mmol/l*min. Values for AUC and IAUC for serum insulin, plasma GLP-1,
and plasma GLP-2 are measures as pmol/l*min. *=p-values less than 0.05 and **=p-values less than 0.01.
doi:10.1371/journal.pone.0023907.g002
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PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e23907of obesity and glucose homeostasis in the fasting state, after an oral
glucose load and following a meal test.
PCSK1 variants and anthropometric measurements
When estimating the effect of the variants on body composition
in the Inter99 study population, only the rs6235 C-allele associated
with increased waist circumference and waist-to-hip ratio; yet only
among men. This sex specific association was not reported in a
Swedish study among 4,923 individuals or in a study among 1,498
non-diabetic Germans [10,13]. In contrast to the results of the
present study, and despite the lack of an interaction between
genotype and sex, a study among 20,249 Europeans found an
association between the rs6235 C-allele and increased risk of obesity
in women [11]. Yet, both studies find that the C-allele of rs6235
associates with an increased measure of body weight. Therefore, the
lack of association among women in the present study may be a
result of a reduced statistical power in the sex-stratified analyses.
Thus, the ambiguous interaction with sex needs further investigation.
The G-allele of rs6232 has previously been shown to have a
functional impact on the catalytic activity [8] and Kilpela ¨inen and
colleagues reported an association between the G-allele of rs6232
and both obesity and BMI, yet, only among individuals younger
than 59 years of age [11]. The present study failed to demonstrate
similar relationships of the same variant to measures of obesity or
age of onset.
When we combined the outcomes of the previous studies of
PCSK1 variants on body composition [11,13] with the outcome of
the present study, the rs6232 G-allele was significantly associated
with increased waist/hip ratio and the rs6235 C-allele with
increased waist circumference irrespective of sex and age. Thus,
despite ambiguous reports, we suggest that both variants have an
effect on measures of obesity and we project that a larger meta-
analysis is needed to substantiate a significant effect of these
variants for risk of obesity.
PCSK1 variants and glucose homeostasis
The rs6235 C-allele associated with reduced levels of fasting
plasma glucose and increased levels of serum insulin after an oral
glucose load among individuals having abnormal glucose regula-
tion. Rs6235 C-allele carriers also displayed elevated post-prandial
serum GIP levels and elevated plasma glucagon. However, we did
not find the previously reported elevation of proinsulin and
insulin/proinsulin levels [13], which may be due to lack of
statistical power of the present study. The meal-challenge analyses
were only performed among men; therefore, we do not know
whether the associations with GIP and glucagon are sex-specific
effects of rs6235.
It is surprising that a variant located in the gene encoding PC1/
3, is associated with increased levels of GIP. Yet, PC1/3 is
involved in the processing of several hormones essential to glucose
regulation and there may exist several underlying mechanism
affecting GIP levels. The elevated level of glucagon is likely a
consequence of the glucagonotrophic effect of GIP [21].
Based on the present results, we propose that a direct or indirect
consequence of having the C-allele of rs6235 is an increased GIP
level - possible only among men. This may be the cause of the
increased level of circulating insulin leading to reduced glycaemia
as well as increased uptake of nutrients causing increased waist
circumference. This hypothesis is in line with the previously
observed protective effect of rs6235 on the development of type 2
diabetes [10]. Interestingly, increasing evidence suggests that GIP
and its receptor-mediated effects are a key link between consump-
tion of energy-rich high-fat diets and the development of obesity
[22].
It may seem contradictory that a variant is associated with
increased body weight as well as protection from the development
of type 2 diabetes. However, the obese and hyperproinsulinemic
Pc1
N222D/N222D mutant mice, which have a mutation in the highly
conserved codon 222 localized to the catalytic domain of PC1/3,
escape diabetes by b-cell expansion and increased secretion of a
less active form of insulin due to improper insulin processing [23].
Additionally, post-prandial hypoglycemia is one of the character-
istic features of the few reported cases of human PC1/3 deficiency
apart from obesity and hyperproinsulinimia [4,24]. Thus, there is
consistent evidence that the PCSK1 may be involved in
mechanisms related both to protection from type 2 diabetes and
risk of obesity.
Examination of the effect of PCSK1 rs6232 during the meal test
revealed that G-allele carriers also have significantly elevated
circulating GLP-1 levels as well as lower post-prandial AUC for
glucose and elevated glucagon level. The mechanisms behind
these associations are not obvious as this variant has been shown to
cause a 10% reduction in the function of PC1/3. Yet, the elevated
concentration of glucagon may result from the lower level of
glucose. Our results are discordant with a study among 1,498 non-
diabetic Germans which found an association between this variant
and decreased fasting insulin levels, reduced levels of insulin
sensitivity, and higher levels of proinsulin following glucose
ingestion [13]. The discrepancy between the two studies may
result from the German study including individuals having an
increased risk of type 2 diabetes in contrast to the present
investigation which was a population-based study.
We have corrected our data for the inclusion of two SNPs,
however, results were not corrected for the number of test
performed for each variant. Obviously, due to the explorative
nature of the present analyses, our suggestive findings need
further examination in other random samples of comparable
populations.
In conclusion, the two common PCSK1 variants, rs6232 and
rs6235, associate with measures of body composition – with a
possible interaction with sex for the rs6235. This variant is also in a
subgroup of 62 glucose tolerant men associated with various
measures of altered postprandial glucose metabolism and
increased serum GIP levels. The G-allele of rs6232 was associated
with increased serum GLP-1 in the same subgroup. If replicated
these results support the hypothesis that the examined PCSK1
variants affect various circulating products of the PC1/3.
Supporting Information
Figure S1 Measures, AUC and IAUC serum proinsulin in 62
carriers of PCSK1 rs6232 (A) and rs6235 (B) undergoing a
standardized meal test. Data are means 6 standard error. IAUC:
Incremental Area Under the Curve, *=p-values less than 0.05
and **=p-values less than 0.01.
(TIF)
Figure 3. Measures of plasma glucose (A), serum insulin (B), plasma GLP-1 (C), and plasma GIP (D), plasma GLP-2 (E) and plasma
glucagon (F) in 62 carriers of PCSK1 rs6235 undergoing a standardized meal test. Data are means 6 standard error. Values for Area Under
the Curve (AUC) and incremental AUC (IAUC) plasma glucose are measured as mmol/l*min. Values for AUC and IAUC for serum insulin, plasma GLP-1,
and plasma GLP-2 are measures as pmol/l*min. *=p-values less than 0.05 and **=p-values less than 0.01.
doi:10.1371/journal.pone.0023907.g003
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